1
|
DeRosa AA, Holzmer S, Ball JJ, Watkins LP, Blanding M, Alley M, Short TH, Bechtol DT, Waite AR, Rigoni EJ, Tena JK. Comparative growth performance of backgrounded beef heifers treated with an injectable fixed-dose combination (0.2 mg/kg doramectin + 6.0 mg/kg levamisole hydrochloride) or single-active (0.2 mg/kg ivermectin) endectocide. Vet Parasitol 2023; 323S:110054. [PMID: 37879976 DOI: 10.1016/j.vetpar.2023.110054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 10/13/2023] [Accepted: 10/13/2023] [Indexed: 10/27/2023]
Abstract
Gastrointestinal nematodes (GINs) can negatively impact all production classes of cattle, particularly growing cattle. A global decline in efficacy of broad-spectrum single-active anthelmintics requires alternative GIN control methods without the aid of novel drug classes. Here, we present a new fixed-dose combination injectable (FDCI) endectocide for cattle that combines doramectin (5 mg/ml) and levamisole hydrochloride (150 mg/ml). A 56-day comparative performance confinement backgrounding trial was conducted in stocker beef heifers (n = 1548) with confirmed GIN infections to (1) compare the Day 14 post-treatment effectiveness of the new FDCI endectocide to pen mates treated with the injectable single-active endectocide ivermectin, as evidenced by fecal egg counts (FECs) conducted for a randomly selected subset (10%) of both treatment groups, and (2) determine if the greater GIN control by the FDCI evidenced in the subsample improved growth performance in all FDCI-treated heifers. Heifers were procured in four cohorts, with a 10-week timeframe between enrollment of the first and last cohort. Treatment groups were comingled within dirt-floor pens (n = 31; 7-8 per cohort) and offered a standard backgrounding diet ad libitum for the study duration. Heifers with enrollment FEC ≥ 30 eggs per gram (EPG) were randomly allocated to receive the FDCI (n = 773) or ivermectin (n = 775) on Day 0. Day 0 FECs conducted on 10% of enrolled heifers (FDCI, n = 78; ivermectin, n = 79) were not different between treatment groups (p = 0.491). Day 14 FECs for the same heifers were reduced compared to Day 0 within each treatment group. Heifers given the FDCI had lower Day 14 AM FECs and higher FEC reduction test (FECRT) result (0.07 EPG; 0.999) than ivermectin-treated heifers (21.58 EPG; FECRT = 0.850). Mean body weight (BW) was not different between treatment groups on Day 0 (p = 0.2762) and Day 14 (p = 0.2010) but was significantly greater (p = 0.0007) for FDCI-treated heifers compared to ivermectin-treated heifers on Day 56. Compared to ivermectin-treated heifers, overall average daily gain from all evaluation periods (Day 0-14, Day 14-56, and Day 0-56) was greater (p ≤ 0.0052) in FDCI-treated heifers, and FDCI-treated heifers had 4.223 kg greater total weight gain over the 56-day study. The FDCI (0.2 mg/kg doramectin + 6.0 mg/kg levamisole hydrochloride) was highly effective in reducing GIN infections and thus promoted improved growth performance in beef heifers over a 56-day backgrounding period.
Collapse
Affiliation(s)
| | - Susan Holzmer
- Zoetis, 333 Portage Street, Kalamazoo, MI 49007, USA
| | - Jase J Ball
- Zoetis, 333 Portage Street, Kalamazoo, MI 49007, USA
| | | | | | - Mark Alley
- Zoetis, 333 Portage Street, Kalamazoo, MI 49007, USA
| | | | | | - Audie R Waite
- Agri Research, LLC, 17001 Hope Road, Canyon, TX 79015, USA
| | | | | |
Collapse
|
2
|
Ball JJ, Taube PC, Hallberg JW, Wood-Follis SL, Dykstra CR, Nadrasik AN, Eberhart NL, Jones SL, Borchers KD, Scramlin JA, Bechtol DT, Waite AR, Edmonds MD, Herrick RT, Lechtenberg KF, Lawrence TE. Synovex ONE Grower improves growth performance for at least 200 days in growing beef steers and heifers fed in confinement for slaughter. Transl Anim Sci 2022; 6:txac109. [PMID: 36196231 PMCID: PMC9525376 DOI: 10.1093/tas/txac109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2022] [Accepted: 08/31/2022] [Indexed: 11/12/2022] Open
Abstract
Growth-promoting implants are broadly used in the feedlot industry to improve growth performance and to increase production efficiencies. With cattle being fed longer and to heavier weights, there is demand for extended-release implants that payout for at least 200 d. Our objective was to evaluate feedlot growth of Synovex ONE Grower, a moderate potency (150 mg trenbolone acetate [TBA] and 21 mg estradiol benzoate [EB]), extended-release, growth-promoting implant for 200 d. At four locations (Texas, Idaho, California, and Nebraska), 200 steers (n = 800; d 0 body weight [BW] = 320.2 ± 9.5 kg) and 200 heifers (n = 800; d 0 BW = 311.5 ± 9.5 kg) were blocked by BW and randomized to 1 of 2 treatments: 1) Control, empty subcutaneous needle inserted and extracted from the middle third of one ear; 2) ONE Grower, 150 mg TBA and 21 mg EB extended-release implant administered in middle third of one ear. Treatments were commingled within pen of the same sex (n = 4/site; 2/sex/site) in a split plot design replicated across four sites. Cattle were fed finishing ration ad libitum common to each geographical region at least once daily and were observed for any abnormal health events twice daily. Treatments were administered on d 0. Mid-study implant site evaluations were performed on d 35 or 41. Initial BW was recorded on d 0 and final BW was recorded on d 200 to 204. Cattle were harvested from d 201 to 231; however, carcass data were not collected due to slaughter facility complications brought on by the COVID-19 pandemic. Data were analyzed using the PROC MIXED and PROC GLIMMIX procedures of SAS (Version 9.4, SAS Institute, Cary, NC; P < 0.05), and animal was the experimental unit. There were no treatment × sex interactions (P ≥ 0.052) for any variable. Final BW on d 200 was greater (P < 0.01) for steers and heifers implanted with ONE Grower compared to Control; ONE Grower improved final BW by 5.7% for steers and 3.9% for heifers. Overall average daily gain (ADG) from d 0 to 200 was greater (P < 0.01) for ONE Grower steers and heifers compared to Control with an increase in ADG of 13.1% for steers and 8.9% for heifers. For cattle implanted with ONE Grower, implant retention rates at d 35 or 41 were 95.7% and 96.3% for steers and heifers, respectively. There was no difference (P ≥ 0.32) in percentage deads, removals, or bullers (steers) between treatments. Synovex ONE Grower improved final BW and ADG in feedlot steers and heifers fed for at least 200 d.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | - Ryan T Herrick
- HMS Veterinary Development, Inc. , Tulare, CA 93274 , USA
| | | | - Ty E Lawrence
- Beef Carcass Research Center, West Texas A&M University , Canyon, TX 79016 , USA
| |
Collapse
|
3
|
Sarchet JJ, Pollreisz JP, Bechtol DT, Blanding MR, Saltman RL, Taube PC. Limitations of bacterial culture, viral PCR, and tulathromycin susceptibility from upper respiratory tract samples in predicting clinical outcome of tulathromycin control or treatment of bovine respiratory disease in high-risk feeder heifers. PLoS One 2022; 17:e0247213. [PMID: 35143504 PMCID: PMC8830659 DOI: 10.1371/journal.pone.0247213] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Accepted: 01/09/2022] [Indexed: 01/08/2023] Open
Abstract
A cross-sectional prospective cohort study including 1026 heifers administered tulathromycin due to high risk of clinical signs of bovine respiratory disease (BRD), measured poor association between BRD clinical outcomes and results of bacterial culture and tulathromycin susceptibility from BRD isolates of deep nasopharyngeal swabs (DNS) and adequate association with viral polymerase chain reaction (PCR) results from nasal swabs. Isolation rates from DNS collected on day-0 and at 1st BRD-treatment respectively were: Mannheimia haemolytica (10.9% & 34.1%); Pasteurella multocida (10.4% & 7.4%); Mycoplasma bovis (1.0% & 36.6%); and Histophilus somni (0.7% & 6.3%). Prevalence of BRD viral nucleic acid on nasal swabs collected exclusively at 1st BRD-treatment were: bovine parainfluenza virus type-3 (bPIV-3) 34.1%; bovine viral diarrhea virus (BVDV) 26.3%; bovine herpes virus type-1 (BHV-1) 10.8%; and bovine respiratory syncytial virus (BRSV) 54.1%. Increased relative risk, at 95% confidence intervals, of 1st BRD-treatment failure was associated with positive viral PCR results: BVDV 1.39 (1.17-1.66), bPIV-3 1.26 (1.06-1.51), BHV-1 1.52 (1.25-1.83), and BRSV 1.35 (1.11-1.63) from nasal swabs collected at 1st BRD-treatment and culture of M. haemolytica 1.23 (1.00-1.51) from DNS collected at day-0. However, in this population of high-risk feeder heifers, the predictive values of susceptible and resistant isolates had inadequate association with BRD clinical outcome. These results indicate, that using tulathromycin susceptibility testing of isolates of M. haemolytica or P. multocida from DNS collected on arrival or at 1st BRD-treatment to evaluate tulathromycin clinical efficacy, is unreliable.
Collapse
MESH Headings
- Animals
- Anti-Bacterial Agents/pharmacology
- Anti-Bacterial Agents/therapeutic use
- Bovine Respiratory Disease Complex/drug therapy
- Bovine Respiratory Disease Complex/microbiology
- Bovine Respiratory Disease Complex/pathology
- Cattle
- Cattle Diseases/drug therapy
- Cattle Diseases/microbiology
- Cattle Diseases/pathology
- Cross-Sectional Studies
- DNA, Viral/genetics
- DNA, Viral/metabolism
- Diarrhea Viruses, Bovine Viral/drug effects
- Diarrhea Viruses, Bovine Viral/genetics
- Diarrhea Viruses, Bovine Viral/isolation & purification
- Disaccharides/pharmacology
- Disaccharides/therapeutic use
- Herpesvirus 1, Bovine/drug effects
- Herpesvirus 1, Bovine/genetics
- Herpesvirus 1, Bovine/isolation & purification
- Heterocyclic Compounds/pharmacology
- Heterocyclic Compounds/therapeutic use
- Mannheimia haemolytica/drug effects
- Mannheimia haemolytica/isolation & purification
- Microbial Sensitivity Tests
- Nasopharynx/microbiology
- Nasopharynx/virology
- Pasteurella multocida/drug effects
- Pasteurella multocida/isolation & purification
- Polymerase Chain Reaction
- Prospective Studies
- RNA, Viral/genetics
- RNA, Viral/metabolism
- Respiratory Syncytial Virus, Bovine/drug effects
- Respiratory Syncytial Virus, Bovine/genetics
- Respiratory Syncytial Virus, Bovine/isolation & purification
- Risk Factors
- Treatment Failure
Collapse
Affiliation(s)
- Jeffrey J. Sarchet
- Zoetis, Parsippany-Troy Hills, New Jersey, United States of America
- * E-mail:
| | | | | | | | - Roger L. Saltman
- Zoetis, Parsippany-Troy Hills, New Jersey, United States of America
| | - Patrick C. Taube
- Zoetis, Parsippany-Troy Hills, New Jersey, United States of America
| |
Collapse
|
4
|
Cleale RM, Amodie D, Bechtol DT, Drouillard JS, Edmonds JD, Edmonds M, Hunsaker BD, Kraft LA, Lawrence TE, Rulli RD, Waite AR. Effects of estradiol benzoate and trenbolone acetate, alone or in combination at dose levels present in Synovex Choice, on performance by feedlot heifers. J Anim Sci 2013; 91:970-7. [PMID: 23307845 DOI: 10.2527/jas.2012-5214] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Trials were conducted with beef heifers at 4 sites to evaluate feedlot performance and carcass characteristics in response to implants containing 14 mg estradiol benzoate and 100 mg trenbolone acetate (EB/TBA; Synovex Choice, Zoetis LLC, New York, NY), 14 mg estradiol benzoate (EB), 100 mg trenbolone acetate (TBA), or a sham-implanted control (SC). The study design at each site was a randomized complete block with 12 blocks and 4 treatments. Blocks of cattle at each site were harvested in commercial abattoirs when masked personnel estimated at least 60% of animals would yield carcasses with USDA quality grades of Choice or Prime. Data were pooled across sites for statistical analysis. Initial BW averaged 374 kg, and days on feed ranged from 98 to 126 d (mean 112 d). Heifers implanted with EB/TBA, EB, and TBA had greater ADG and G:F (P < 0.05) than SC; ADG and G:F were greater for EB/TBA than EB or TBA (P < 0.05). Heifers treated with TBA had greater G:F than EB (P < 0.05). Feed intake was not affected by treatments. Mean HCW and LM area for EB/TBA were greater than for other treatments (P < 0.05). Mean HCW for TBA was greater than SC (P < 0.05) but not different from EB. Mean LM area for EB and TBA were greater than SC (P < 0.05) but not different from each other. There were no treatment differences (P > 0.05) for KPH, 12th-rib fat thickness, or yield grade. Dressing percent was greater for EB/TBA than SC (P < 0.05) but not different from EB or TBA. Marbling score was decreased by EB/TBA (P < 0.05) compared with other treatments, but no other differences were noted. Despite the effect of EB/TBA on marbling scores, there were no significant (P > 0.05) treatment differences on proportions of carcasses with quality grades ≥ Choice vs. < Choice. With respect to ADG and G:F, implants containing EB, TBA, or EB/TBA produced improved responses over SC. Furthermore, EB/TBA induced greater ADG and G:F responses than EB and TBA. Results confirmed that EB and TBA have additive effects, as evidenced by the observation that calves implanted with EB/TBA had significantly greater ADG and G:F than heifers implanted with either EB or TBA alone or compared with SC heifers.
Collapse
|
5
|
Cleale RM, Bechtol DT, Drouillard JS, Edmonds JD, Edmonds M, Hunsaker BD, Kraft LA, Lawrence TE, Brewbaker S, Waite AR. Synovex Plus implants coated with a polymeric, porous film improve performance of beef steers and heifers fed in confinement for up to 200 days. J Anim Sci 2012; 90:5056-66. [PMID: 23100600 DOI: 10.2527/jas.2012-5091] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Synovex Plus (SP) is a product that delivers 28 mg of estradiol benzoate (EB) and 200 mg of trenbolone acetate (TBA). We studied the impact of a polymeric, porous coating on SP implants (CSP) to prolong release of EB and TBA, and stimulate feedlot performance of feedlot cattle for an extended period. In an explant study, 30 steers were implanted with SP in one ear and CSP in the contralateral ear. Cattle (n = 6/d) were necropsied 40, 81, 120, 160, and 200 d after treatment, and remaining EB and TBA were quantified. Linear regression of EB and TBA remaining as a function of time for each treatment were computed. Rates of EB and TBA depletion from SP were -0.1980 (r(2) = 0.9994) and -1.7073 mg/d (r(2) = 0.9644), respectively, and for CSP rates of EB and TBA depletion were -0.1049 (r(2) = 0.9123) and -0.9466 mg/d (r(2) = 0.9297), respectively. The effect of treatment on depletion rates of each analyte were significant (P < 0.05). Data also showed EB and TBA were delivered from CSP at least 200 d but were delivered from SP about 120 d. Multisite trials with beef-type steers (4 sites) and heifers (4 sites) evaluated feedlot performance and carcass characteristics in response to a CSP implant or when sham implanted (SC). A randomized complete block design with 9 blocks and 2 treatments was used per site within animal gender. Across sites, steers (n = 342, BW = 297 kg) were fed finishing rations for 190 to 202 d (mean 198 d) and heifers (n = 342, BW = 289 kg) were fed finishing rations for 191 to 201 d (mean 198 d). Cattle were harvested and carcasses evaluated. Data were pooled across sites within gender for statistical analysis. Steers and heifers treated with CSP yielded greater (P ≤ 0.003) ADG, DMI, and G:F than SC steers and heifers. Mean BW differences between CSP and SC continued to increase throughout the study, indicating CSP stimulated growth of steers and heifers for 198 d. Mean carcass weights of CSP steers (P = 0.005) and heifers (P = 0.004) were greater than those of SP steers and heifers by 26.2 and 20.6 kg, respectively. The LM area was larger (P < 0.001) in CSP steers and heifers than SC cattle. Marbling decreased with CSP treatment (P ≤ 0.031), which caused reductions (P ≤ 0.006) in proportions of carcasses grading Prime or Choice. Evidence from these studies showed that a single administration of CSP increased feedlot cattle performance for at least 198 d, compared with SC, and may reduce the need to reimplant cattle.
Collapse
Affiliation(s)
- R M Cleale
- Pfizer Animal Health, 5 Giralda Farms, Madison, NJ 07940, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Stromberg BE, Gasbarre LC, Waite A, Bechtol DT, Brown MS, Robinson NA, Olson EJ, Newcomb H. Cooperia punctata: Effect on cattle productivity? Vet Parasitol 2012; 183:284-91. [DOI: 10.1016/j.vetpar.2011.07.030] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2011] [Revised: 07/06/2011] [Accepted: 07/13/2011] [Indexed: 10/18/2022]
|
7
|
Step DL, Krehbiel CR, Burciaga-Robles LO, Holland BP, Fulton RW, Confer AW, Bechtol DT, Brister DL, Hutcheson JP, Newcomb HL. Comparison of single vaccination versus revaccination with a modified-live virus vaccine containing bovine herpesvirus-1, bovine viral diarrhea virus (types 1a and 2a), parainfluenza type 3 virus, and bovine respiratory syncytial virus in the prevention of bovine respiratory disease in cattle. J Am Vet Med Assoc 2009; 235:580-7. [PMID: 19719452 DOI: 10.2460/javma.235.5.580] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Objective-To compare effects of administration of a modified-live respiratory virus vaccine once with administration of the same vaccine twice on the health and performance of cattle. Design-Randomized, controlled trial. Animals-612 mixed-breed male cattle with unknown health histories. Procedures-Cattle were randomly assigned to 1 of 2 treatment groups (single vaccination treatment group [SVAC group] vs revaccination treatment group [REVAC group]) during the preconditioning phase of production. All cattle were given a modified-live respiratory virus vaccine. Eleven days later, REVAC group cattle received a second injection of the same vaccine. During the finishing phase of production, cattle from each treatment group were either vaccinated a third time with the modified-live respiratory virus vaccine or given no vaccine. Health observations were performed daily. Blood and performance variables were measured throughout the experiment. Results-During preconditioning, no significant differences were observed in performance or antibody production between groups. Morbidity rate from bovine respiratory disease was lower for SVAC group cattle; however, days to first treatment for bovine respiratory disease were not different between groups. No significant differences in body weights, daily gains, or dry-matter intake between groups were observed during the finishing phase. Revaccination treatment group cattle had improved feed efficiency regardless of vaccination protocol in the finishing phase. Conclusions and Clinical Relevance-Vaccination once with a modified-live respiratory virus vaccine was as efficacious as vaccination twice in the prevention of bovine respiratory disease of high-risk cattle, although feed efficiency was improved in REVAC group cattle during the finishing period.
Collapse
Affiliation(s)
- Douglas L Step
- Department of Veterinary Clinical Sciences, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK 74078, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Montgomery JL, Krehbiel CR, Cranston JJ, Yates DA, Hutcheson JP, Nichols WT, Streeter MN, Bechtol DT, Johnson E, TerHune T, Montgomery TH. Dietary zilpaterol hydrochloride. I. Feedlot performance and carcass traits of steers and heifers. J Anim Sci 2008; 87:1374-83. [PMID: 19098247 DOI: 10.2527/jas.2008-1162] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Experiments were conducted at 3 US locations (CA, ID, and TX) to determine the effects of dietary zilpaterol hydrochloride (Zilmax, Intervet Inc., Millsboro, DE) and duration of zilpaterol feeding on performance and carcass merit of finishing steers and heifers. At each site, 160 steers and 160 heifers were stratified within sex by initial BW (study d -1) and assigned randomly within BW strata to 1 of 4 treatments in a randomized complete block design (4 blocks/treatment for each sex). The 4 treatments were arranged in a 2 (no zilpaterol vs. zilpaterol) x 2 (20 or 40 d duration of zilpaterol feeding) factorial arrangement of treatments. When included in the diet, zilpaterol was supplemented at 8.3 mg/kg of DM. Each pen consisted of 10 animals. Each animal was individually weighed unshrunk on d 1, 21 or 41, and 66 of the experiment. Following d 66, cattle were slaughtered and carcass data collected. Feeding zilpaterol increased (P<0.01) final BW of steers and heifers by 11.6 and 6.7 kg, respectively. In addition, feeding zilpaterol hydrochloride increased (P <or= 0.001) ADG 36 and 18%, and increased (P<0.001) G:F 28 and 21% for steers and heifers, respectively. For heifers, DMI was decreased (P<0.001) 6.2% when zilpaterol was fed, whereas in steers DMI tended (P=0.09) to be decreased 2%. For steers and heifers, feeding zilpaterol increased (P<0.001) HCW 16.4 and 12.1 kg, dressing percentage 1.5 percentage units for each sex, and LM area 8.23 and 6.37 cm(2), respectively. Twelfth-rib fat (P >or= 0.12) and KPH (P >or= 0.70) were not affected by feeding zilpaterol to steers or heifers. Feeding zilpaterol decreased (i.e., improved; P=0.02) calculated yield grade of steer and heifer carcasses. Marbling score (P=0.002) and quality grade (P=0.002) were decreased when zilpaterol hydrochloride was fed to steers, and the decrease in marbling score and quality grade tended to be greater when zilpaterol was fed for 40 compared with 20 d (zilpaterol x duration interaction, P=0.07). For heifers, marbling score tended (P=0.07) to be decreased and quality grade was decreased (P=0.05) when zilpaterol hydrochloride was fed. In general, it appears from these data that zilpaterol hydrochloride fed for 20 to 40 d at the end of the finishing period enhances growth performance and carcass muscle deposition for steers and heifers.
Collapse
|
9
|
Ballweber LR, Brown J, Hawkins JA, Bechtol DT, Black S, Alva R, Plue RE. Comparison of ivermectin SR bolus, benzimidazole anthelmintics, and topical fenthion on productivity of stocker cattle from grazing through feedlot. Vet Ther 2000; 1:192-198. [PMID: 19757582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A study was conducted to determine the effect of different parasite control programs on weight gain and other measurements for stocker beef calves during the grazing season and subsequent feedlot phase of production. One hundred eighty recently weaned beef steers were purchased from a Mississippi sale barn and were allocated by restricted randomization on pretreatment weight to three treatments: (1) no anthelmintic treatment; treated only with a topical organophosphate (OP) during processing into the feedlot; (2) one benzimidazole (BZD) treatment at initiation of grazing, and a second given at the time of processing upon arrival at the feedlot, along with a topical OP; and (3) ivermectin sustained-release (SR) bolus administered at initiation of grazing, with no further treatment given at the feedlot. The cattle grazed separately by treatment for 125 days, with six replicated pastures per treatment; then were penned according to the same groupings after entry into the feedlot on day 127. Cattle were individually weighed at approximately 2-month intervals, and feed consumption was measured during the 167 days in the feedlot. Fecal nematode egg counts were individually monitored for all animals during both phases of the trial. Carcass weight, quality grade, yield grade, and the incidence of liver abscesses were recorded for each animal at slaughter. Cattle treated with the ivermectin SR bolus gained significantly (P < .05) more weight through the grazing period and from the start of grazing through the end of the feedlot phase than the controls or the cattle treated with BZD products. There were no significant differences in feed efficiency between any of the groups. Mean carcass weight for cattle treated with boluses was significantly (P < .05) greater than that of the controls and the group treated with BZD. Dressing percentage and quality grade were significantly (P < .05) higher for the BZD and bolus groups, and yield grade was slightly (but not significantly) better for each of these groups than for controls. Significantly (P < .05) fewer livers of cattle treated with boluses had abscesses at slaughter than did livers of controls or cattle treated with BZDs. During both phases of the trial, fecal egg counts were significantly (P < .05) lower for the group treated with boluses than for the untreated group or the group treated with BZD. These data indicate that treatment with boluses for parasite control at the beginning of the grazing period had beneficial effects on weight gain as compared to no anthelmintic treatment or treatment with a BZD at the start of grazing and again at the time of introduction into the feedlot. These bolus benefits were sustained through the feedlot phase of production and provided further improvements with significantly (P < .05) increased carcass weights. The bolus is a tool that can significantly increase the efficiency of production for cattle producers who retain ownership into the feedlot phase of production or feedlot operators who graze stockers before feedlot entry.
Collapse
Affiliation(s)
- L R Ballweber
- College of Veterinary Medicine, Box 9825, Mississippi State University, Starkville, MS 39762, USA
| | | | | | | | | | | | | |
Collapse
|
10
|
Kesler DJ, Bechtol DT. Efficacy of sustained release needle-less ceftiofur sodium implants in treating calves with bovine respiratory disease. Zentralbl Veterinarmed B 1999; 46:25-35. [PMID: 10085771 DOI: 10.1046/j.1439-0450.1999.00194.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Three experiments were conducted to determine preliminary efficacy of sustained release needle-less implants in effecting cure in calves with bovine respiratory disease. One hundred and twenty beef calves with a rectal temperature > or = 40 degrees C and shallow or labored respiration and coughing were used in these experiments. Four groups (1-ceftiofur sodium injections [days 1, 2, and 3], 2-ceftiofur sodium needle-less implants [days 1, 2, and 3], 3-ceftiofur sodium needle-less implants [days 1 and 3], and 4-ceftiofur sodium needle-less implants [day 1] were included. All treatments contained 250 mg of ceftiofur sodium and were administered intramuscularly in the neck after diagnosis of bovine respiratory disease. Experiment 1 included 20 calves (group 1-10 calves and group 3-10 calves; 213 to 255 kg) and calves were monitored for clinical efficacy. Experiment 2 included five calves per group (all four groups; 164 to 192 kg) and calves were bled frequently after treatment for desfuroylceftiofur (the primary ceftiofur metabolite) concentrations. Experiment 3 included 20 calves per group (all four groups; 160 to 205 kg) and calves were monitored for clinical efficacy. Blood desfuroylceftiofur concentrations remained above the minimum inhibitory concentration for Pasteurella haemolytica, Pasteurella multocida, and Haemophilus somnus for 24 hours after injection and 72 hours after implantation (P < 0.05). Mortalities and the number of calves with a positive response and relapse response were similar (P < 0.25) among the four groups. In summary, the administration of one-250 mg ceftiofur sodium needle-less sustained release implant was as efficacious in treating bovine respiratory disease as three daily 250 mg injections of ceftiofur sodium.
Collapse
Affiliation(s)
- D J Kesler
- Antech Laboratories, Inc., Savoy, IL 61874, USA
| | | |
Collapse
|
11
|
Rogers JA, Branine ME, Miller CR, Wray MI, Bartle SJ, Preston RL, Gill DR, Pritchard RH, Stilborn RP, Bechtol DT. Effects of dietary virginiamycin on performance and liver abscess incidence in feedlot cattle. J Anim Sci 1995; 73:9-20. [PMID: 7601759 DOI: 10.2527/1995.7319] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
The effects of dietary virginiamycin level on performance and liver abscesses in feedlot cattle were evaluated in seven dose-response studies. Steers and heifers were fed finishing diets ranging in energy content from 1.34 to 1.51 Mcal of NEg/kg of DM. In all studies, virginiamycin added to the diet improved average daily gain and(or) feed conversion, with no substantial effect on dry matter intake. Pooled analyses of four studies providing virginiamycin at 11.0, 19.3, and 27.6 mg/kg of DM in the complete diet indicated that growth and feed conversion were linearly improved (P < .05); feeding 19.3 mg/kg improved these measurements by 3.0 and 3.8%, respectively. Overall incidence (score 0 vs score 1, 2, and 3) and severity (score 0, 1, and 2 vs score 3) of liver abscesses were reduced (P < .01) by feeding virginiamycin at either 19.3 or 27.6 mg/kg. Linear plateau modeling indicated that the effective dose range for virginiamycin in feedlot diets (DM basis) was 19.3 to 27.3 mg/kg for increasing average daily gain, 13.2 to 19.3 mg/kg for improving feed conversion, and 16.5 to 19.3 mg/kg for reducing liver abscess incidence.
Collapse
Affiliation(s)
- J A Rogers
- SmithKline Beecham Animal Health, West Chester, PA 19380
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
Mass medication is a health management tool that, when used appropriately, results in cost savings and sound economic return to the food animal producer. Careful planning and consideration should precede the implementation of a mass treatment program, clearly defining the goal to be achieved and a detailed plan of execution. For economic as well as professional reasons, indiscriminate administration of antimicrobials to large groups of food animals should be avoided.
Collapse
|